Bassam Kanaan - Hikma Pharmaceuticals Chief Strategy & Corporate Development Officer
| HKMPF Stock | USD 22.33 1.92 7.92% |
Executive
Mr. Bassam Wael Rushdi Kanaan is Chief Strategy and Corporationrationrate Development Officer of Hikma Pharmaceuticals Plc. Bassam has Group level responsibility for strategic development, acquisitions, alliances, product development, and risk. Bassam has held several executive positions during 17 years with Hikma, including Chief Financial Officer. US Certified Public Accountant and Chartered Financial Analyst. BA from Claremont McKenna. International Executive MBA from Kellogg Recanati Schools of Management. since 2014.
| Age | 52 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 44 20 7399 2760 |
| Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Hourigan | Arrow Electronics | N/A | |
| Boaz Magid | PennantPark Floating Rate | 46 | |
| Steve Kerdock | Arrow Electronics | N/A | |
| Richard Seidlitz | Arrow Electronics | 45 | |
| Janene Asgeirsson | Analog Devices | 54 | |
| Darlan Monterisi | Playtika Holding Corp | N/A | |
| Randy Berg | Transphorm Technology | N/A | |
| Richard Houten | PennantPark Floating Rate | N/A | |
| Michael Lucarelli | Analog Devices | N/A | |
| Daniel Leibholz | Analog Devices | N/A | |
| Mariya Trickett | Analog Devices | 40 | |
| Anelise Sacks | Analog Devices | 45 | |
| Michael Esq | Playtika Holding Corp | 53 | |
| Scott McCabe | PennantPark Floating Rate | N/A | |
| Howard Goldberg | Arrow Electronics | N/A | |
| Thomas Esq | PennantPark Floating Rate | N/A | |
| Alex Collichio | Allient | N/A | |
| Philip Zuk | Transphorm Technology | N/A | |
| Frank CFA | PennantPark Floating Rate | 56 | |
| Patrick ODoherty | Analog Devices | N/A | |
| Anthony Bencivenga | Arrow Electronics | N/A | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
| Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
| Khalid Nabilsi, Chief Officer | ||
| Hussein Arkhagha, General Counsel | ||
| Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
| Pamela Kirby, Non-Executive Independent Director | ||
| John Castellani, Non-Executive Independent Director | ||
| Brian Hoffman, President and Chief Executive of - Generics Division | ||
| Ali AlHusry, Non-Executive Director | ||
| Jochen Gann, Non-Executive Director | ||
| Engineer Darwazah, Ex CEO | ||
| Peter Speirs, Company Secretary | ||
| Patrick Butler, Non-Executive Independent Director | ||
| Brian Hoffmann, Pres Generics | ||
| Said Darwazah, Chairman and CEO | ||
| Michael Raya, President and CEO, USA | ||
| Samuel Park, Global US | ||
| Ronald Goode, Non-Executive Independent Director | ||
| Bryan Hotston, CIO | ||
| Sigurdur Olafsson, CEO | ||
| Breffni Byrne, Non-Executive Independent Director | ||
| Nina Henderson, Non-Executive Independent Director | ||
| Cynthia Schwalm, Independent Non-Executive Director | ||
| Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
| Michael Ashton, Non-Executive Independent Director | ||
| Majda Labadi, Corporate Vice President - Human Resources | ||
| Ibrahim Jalal, Sr. Corporate VP of Technical Affairs | ||
| Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
| Robert Pickering, Senior Non-Executive Independent Director | ||
| Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
| CPA CFA, Exec MA |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 220.26 M | |||
| Shares Owned By Insiders | 29.67 % | |||
| Shares Owned By Institutions | 41.69 % | |||
| Price To Earning | 7.89 X | |||
| Price To Book | 1.84 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hikma Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hikma Pharmaceuticals' short interest history, or implied volatility extrapolated from Hikma Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |